regulatory status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-13 and is reviewed periodically as new material appears.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Henry Roy Dean - Professor of Pathology and responsible for significant pathology teaching at Cambridge and the current building on Tennis Court Road in 1928. With Ronald Greaves, developed reliable methods for freeze-drying plasma, the process now known as lyophilisation. Andrew Wyllie - Discovered apoptosis, the first process of programmed cell death to be described. He defined the breakdown of DNA during apoptosis and its role in tumour growth Malcolm Ferguson-Smith - Distinguished medical geneticist from Glasgow, held the chair from 1987 to 1998. He emphasised the importance of Pathology in the analysis of the genome and so positioned the department well for the 21st Century. Geoffrey L. Smith - Virologist and medical research authority in the area of Vaccinia virus and the family of Poxviruses. Part of the UK's response to the 2022 Mpox epidemic. Ashley Moffett - Moffett has been at the forefront of research into the immunology of trophoblast invasion and its role in placentation for over 25 years. She became a fellow of the Royal College of Obstetricians and Gynaecologists in 2015, and a fellow of the Academy of Medical Sciences in 2019.
== Pathophysiology == Pathophysiology refers to the physiological processes associated with a disease or injury. In the history of medicine, diseases became better understood as human anatomy became better understood. The development of autopsy in the 15th and 16th centuries was key to this learning. As anatomists detailed the complex structures of the human body, they began to pay more attention to the pathological structures associated with diseases, their causes and effects, and mechanisms of progress. By the 18th century, many such pathologic observations were being published in textbooks and journals. This work lay important foundations for advances in medical treatment and intervention. Historically, various notions of present-day "diabetes" have described some general mix of excessive urine (polyuria), excessive thirst (polydipsia), and weight loss (see: History of diabetes#Early accounts). Over the past few centuries, these symptoms have been linked to updated understandings of how the disease works, and how it manifests differently across cases. This section outlines these developments as various diabetic conditions have become better understood.
DHEA, also known as androst-5-en-3β-ol-17-one, is a naturally occurring androstane steroid and a 17-ketosteroid. It is closely related structurally to androstenediol (androst-5-ene-3β,17β-diol), androstenedione (androst-4-ene-3,17-dione), and testosterone (androst-4-en-17β-ol-3-one). DHEA is the 5-dehydro analogue of epiandrosterone (5α-androstan-3β-ol-17-one) and is also known as 5-dehydroepiandrosterone or as δ5-epiandrosterone.
== Ethical concerns == In fact, HSDD was defined shortly before the release of flibanserin to the market and its approval by the US FDA. This has brought up a controversy about whether it is appropriate and ethical to create a medical condition for the benefit of the sales of pharmaceutical products. Apart from this ethical issue, there is a dilemma of whether a medical doctor should prescribe drugs to sexual offenders whose libido is subpar. On the one hand, it is considered unethical for doctors not to treat them as they are expected to treat patients indiscriminately. On the other hand, treating sexual offenders may impose a risk to society. Physicians have been struggling with this dilemma, and it is still difficult for them to make a choice at this moment in time.
In proper nouns, many Korean monarchs have overly long posthumous names built from many different Sino-Korean nouns describing their positive characteristics, for example Sunjo of Joseon, whose full posthumous name is the 77-syllable-block 순조 선각 연덕현도 경인순희 체성응명흠광석경계천배극융원돈휴의행소윤희화준렬대중지정 홍훈철 모건시태형창 운홍기고명박후강건수정계통수력 공유범문안무정영경 성효대왕 (sunjoseongag-yeondeoghyeondogyeong-insunhuicheseong-eungmyeongheumgwangseoggyeong-gyecheonbaegeug-yung-wondonhyuuihaengsoyunhuihwa-junlyeoldaejungjijeonghonghuncheolmogeonsitaehy-eongchang-unhong-gigomyeongbaghugang-geonsujeong-gyetongsulyeoggong-yubeommun-anmujeong-yeong-gyeongseonghyodaewang). This is simply writing the phrase in Hanja (Hanzi) 純祖先覺淵德顯道景仁純禧體聖凝命欽光錫慶繼天配極隆元敦休懿行昭倫熙化峻烈大中至正洪勳哲謨乾始泰亨昌運弘基高明博厚剛健粹精啓統垂曆建功裕範文安武靖英敬成孝肅皇帝, being transliterate in Hangul. It is not a single word and does not qualify as a lexical entry.
Sources: en.wikipedia.org
== External links == https://web.archive.org/web/20081011174545/http://www.souss.com/Interview-de-Belkacem-Lounes.html "Interview de Belkacem LOUNES, Président du CMA, accordée au journal Marocain Al-Michaal", 30 March 2007, Amazigh World.
Whose power is to be balanced? Today, no nation or group challenges American power … In fact, should the balance of power operate in its classical form, it would trigger countermoves by states seeking to pose a counterweight to America's expressed ambitions. According to Leffler's exegesis, Bush has invoked a balance of power vocabulary in purpose to integrate the tradition with the hegemonic dilemma. British Orwell Prize-winning policy analyst, Anatol Lieven, comments: In this conception, however, a phrase "was a form of Orwellian doublespeak. The clear intention actually was to be so strong that other countries had no choice but to rally to the side of the United States, concentrating all real power and freedom of action in the hands of America." The surprising rehabilitation of the balance-of-power term in the 2002 NSS "can be accounted for in terms of mythopoetic function that the terminology serves in the document." It keeps alive the traditional concept in a new unipolar world.
=== Phase 2 === AB-2004 – microbiome modulator Acamprosate (AOP-2020; Campral; SF-679/SF-775; SF-999) – unknown / GABAA receptor positive allosteric modulator and ionotropic glutamate NMDA receptor antagonist Alogabat (RG-7816, RG7816, RO-7017773; GABA-A-α5 PAM) – GABAA α5 subunit-containing receptor positive allosteric modulator Arbaclofen ((R)-baclofen; STX-209) – GABAB receptor agonist Cannabidiol (CBD; Epidiolex) – cannabinoid receptor modulator, other actions Cannabidiol transdermal patch/gel (Zygel; ZYN-002) – cannabinoid receptor modulator, other actions Cannabidivarin (CBDV; GWP-42006) – non-intoxicating cannabinoid receptor modulator, other actions CP-101 – bacteria relacement and gastrointestinal microbiome modulator JNJ-42165279 (JNJ-5279) – fatty acid amide hydrolase (FAAH) inhibitor Non-racemic MDMA (ALA-002; 70–80% (R)-MDMA, 20–30% (S)-MDMA) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen Oxytocin (intranasal potentiated oxytocin; TI-001, TI-114, TNX-1900, TNX-2900) – oxytocin receptor agonist Pitolisant (Wakix; tiprolisant) – histamine H3 receptor inverse agonist Racemetirosine (DL-α-methyltyrosine; L1-79) – tyrosine hydroxylase inhibitor Suramin (IV suramin; PAX-101/PAX-102) – DNA synthesis inhibitor and anti-purinergic agent Zolmitriptan modified-release (ML-004, ML004) – serotonin 5-HT1B and 5-HT1D receptor agonist
=== Circulatory system === Arenobufagin works like cardiac glycosides. It inhibits the sodium-potassium pump because it stabilises the E2-P transition state, in which the pump is inactive. Second membrane transporter NCX is responsible for 3Na/Ca transport, if the Na-K-Pump does not function correctly the Ca concentration inside the cell will rise and this will cause heart failure. However, in experiments concerning the anti-cancer effects of arenobufagin in mice, no negative effects where found.
Soon after inoculation, yeast begin to rapidly consume the available assimilable nitrogen with up to 46% of YAN being fully consumed by the onset of full fermentation. Because inorganic nitrogen, such as the ammonium salts in DAP, are toxic to yeast in high levels, it is never added during inoculation when the biomass of the newly re-hydrated yeast is low. Many winemakers split up the dosage of DAP with the first addition being made at the end of the lag phase when the yeast enter their period of exponential growth and alcoholic fermentation begins. In most must this is around 48 to 72 hours after inoculation. A second dosage is then often added around a third of the way through sugar fermentation and often before the sugar levels hit 12-10 Brix (6.5 to 5.5 Baumé, 48.3 to 40.0 Oechsle) because as the fermentation progresses yeast cells are no longer able to bring the nitrogen into the cell due to the increasing toxicity of ethanol surrounding the cells. This leaves the nitrogen unused and available for spoilage organisms that may come afterwards.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.